Cargando…
Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between wei...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605511/ https://www.ncbi.nlm.nih.gov/pubmed/36294421 http://dx.doi.org/10.3390/jcm11206100 |
_version_ | 1784818085488754688 |
---|---|
author | Ikoma, Tatsuki Matsumoto, Toshihiko Kurioka, Yusuke Takatani, Masahiro Nagai, Hiroki Matsumoto, Yusuke Satake, Hironaga Yasui, Hisateru |
author_facet | Ikoma, Tatsuki Matsumoto, Toshihiko Kurioka, Yusuke Takatani, Masahiro Nagai, Hiroki Matsumoto, Yusuke Satake, Hironaga Yasui, Hisateru |
author_sort | Ikoma, Tatsuki |
collection | PubMed |
description | Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between weight change and nutritional status up to the start of nivolumab treatment and OS and progression-free survival (PFS) after starting nivolumab treatment was determined. Nutritional status was examined using the C-reactive protein/albumin ratio (CAR). A loss in body weight (LBW) from the onset of the first treatment of <4.5% led to OS prolongation and improved PFS outcomes. The median OS values in the LBW < 4.5% and ≥4.5% groups were 11.4 and 3.6 months, respectively. Similarly, changes in CAR from first-line chemotherapy (ΔCAR) affected OS; the ΔCAR < 0.01 group had a better prognosis than the ΔCAR ≥ 0.01 group. The median OS values in the ΔCAR < 0.01 and ≥0.01 groups were 9.4 and 4.5 months, respectively. The median OS in the group with LBW < 4.5% and ΔCAR < 0.01 was 12.9 months. LBW and deterioration of nutritional status following first-line chemotherapy are poor prognostic factors in AGC patients who received nivolumab as third- or later-line therapy. Early intervention to maintain body weight and nutritional status may improve the efficacy of immune checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-9605511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96055112022-10-27 Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy Ikoma, Tatsuki Matsumoto, Toshihiko Kurioka, Yusuke Takatani, Masahiro Nagai, Hiroki Matsumoto, Yusuke Satake, Hironaga Yasui, Hisateru J Clin Med Article Nivolumab improves overall survival (OS) in patients with advanced gastric cancer (AGC) refractory to at least two previous chemotherapy regimens. We investigated whether changes in body weight and nutrition from first-line chemotherapy to nivolumab affected its efficacy. The correlation between weight change and nutritional status up to the start of nivolumab treatment and OS and progression-free survival (PFS) after starting nivolumab treatment was determined. Nutritional status was examined using the C-reactive protein/albumin ratio (CAR). A loss in body weight (LBW) from the onset of the first treatment of <4.5% led to OS prolongation and improved PFS outcomes. The median OS values in the LBW < 4.5% and ≥4.5% groups were 11.4 and 3.6 months, respectively. Similarly, changes in CAR from first-line chemotherapy (ΔCAR) affected OS; the ΔCAR < 0.01 group had a better prognosis than the ΔCAR ≥ 0.01 group. The median OS values in the ΔCAR < 0.01 and ≥0.01 groups were 9.4 and 4.5 months, respectively. The median OS in the group with LBW < 4.5% and ΔCAR < 0.01 was 12.9 months. LBW and deterioration of nutritional status following first-line chemotherapy are poor prognostic factors in AGC patients who received nivolumab as third- or later-line therapy. Early intervention to maintain body weight and nutritional status may improve the efficacy of immune checkpoint inhibitors. MDPI 2022-10-17 /pmc/articles/PMC9605511/ /pubmed/36294421 http://dx.doi.org/10.3390/jcm11206100 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ikoma, Tatsuki Matsumoto, Toshihiko Kurioka, Yusuke Takatani, Masahiro Nagai, Hiroki Matsumoto, Yusuke Satake, Hironaga Yasui, Hisateru Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title | Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title_full | Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title_fullStr | Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title_full_unstemmed | Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title_short | Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy |
title_sort | improvement of body weight and nutritional status in gastric cancer patients enhances the benefit of nivolumab therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605511/ https://www.ncbi.nlm.nih.gov/pubmed/36294421 http://dx.doi.org/10.3390/jcm11206100 |
work_keys_str_mv | AT ikomatatsuki improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT matsumototoshihiko improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT kuriokayusuke improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT takatanimasahiro improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT nagaihiroki improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT matsumotoyusuke improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT satakehironaga improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy AT yasuihisateru improvementofbodyweightandnutritionalstatusingastriccancerpatientsenhancesthebenefitofnivolumabtherapy |